206 related articles for article (PubMed ID: 38664825)
1. siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.
Chaudhary P; Yadav K; Lee HJ; Kang KW; Mo J; Kim JA
Breast Cancer Res; 2024 Apr; 26(1):72. PubMed ID: 38664825
[TBL] [Abstract][Full Text] [Related]
2. The long non-coding RNA DANCR regulates the inflammatory phenotype of breast cancer cells and promotes breast cancer progression via EZH2-dependent suppression of SOCS3 transcription.
Zhang KJ; Tan XL; Guo L
Mol Oncol; 2020 Feb; 14(2):309-328. PubMed ID: 31860165
[TBL] [Abstract][Full Text] [Related]
3. EZH2 knockdown in tamoxifen-resistant MCF-7 cells unravels novel targets for regaining sensitivity towards tamoxifen.
Kumari K; Kumar S; Parida DK; Mishra SK
Breast Cancer; 2021 Mar; 28(2):355-367. PubMed ID: 32990923
[TBL] [Abstract][Full Text] [Related]
4. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
[TBL] [Abstract][Full Text] [Related]
5. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
6. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
7. Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity.
Qin T; Li B; Feng X; Fan S; Liu L; Liu D; Mao J; Lu Y; Yang J; Yu X; Zhang Q; Zhang J; Song B; Li M; Li L
J Exp Clin Cancer Res; 2018 Nov; 37(1):287. PubMed ID: 30482232
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling.
Yang Q; Zhao S; Shi Z; Cao L; Liu J; Pan T; Zhou D; Zhang J
J Exp Clin Cancer Res; 2021 Apr; 40(1):120. PubMed ID: 33823894
[TBL] [Abstract][Full Text] [Related]
10. Integrin alpha-2 and beta-1 expression increases through multiple generations of the EDW01 patient-derived xenograft model of breast cancer-insight into their role in epithelial mesenchymal transition in vivo gained from an in vitro model system.
Wafai R; Williams ED; de Souza E; Simpson PT; McCart Reed AE; Kutasovic JR; Waltham M; Snell CE; Blick T; Thompson EW; Hugo HJ
Breast Cancer Res; 2020 Dec; 22(1):136. PubMed ID: 33276802
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
[TBL] [Abstract][Full Text] [Related]
12. The YB-1/EZH2/amphiregulin signaling axis mediates LPA-induced breast cancer cell invasion.
Cho KH; Jeong BY; Park CG; Lee HY
Arch Pharm Res; 2019 Jun; 42(6):519-530. PubMed ID: 31004257
[TBL] [Abstract][Full Text] [Related]
13. Interplay between desmoglein2 and hypoxia controls metastasis in breast cancer.
Chang PH; Chen MC; Tsai YP; Tan GYT; Hsu PH; Jeng YM; Tsai YF; Yang MH; Hwang-Verslues WW
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431674
[TBL] [Abstract][Full Text] [Related]
14. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of Long Noncoding RNA HOTAIR and EZH2 Induces Apoptosis and Inhibits Proliferation, Invasion, and Migration of Human Breast Cancer Cells.
Han L; Zhang HC; Li L; Li CX; Di X; Qu X
Cancer Biother Radiopharm; 2018 Aug; 33(6):241-251. PubMed ID: 30048163
[TBL] [Abstract][Full Text] [Related]
16. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375
[TBL] [Abstract][Full Text] [Related]
17. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
18. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
19. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
[TBL] [Abstract][Full Text] [Related]
20. miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer.
Fu H; Fu L; Xie C; Zuo WS; Liu YS; Zheng MZ; Yu JM
Oncol Rep; 2017 Feb; 37(2):1093-1099. PubMed ID: 28075453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
